Global Rett Syndrome Market Size study, By Type (Classic Rett Syndrome, and Atypical Rett Syndrome), By Treatment (Medication, Physical Therapy, Occupational Therapy, Speech language Therapy, and Nutritional Support), By Route of Administration (Oral, Par

Global Rett Syndrome Market Size study, By Type (Classic Rett Syndrome, and Atypical Rett Syndrome), By Treatment (Medication, Physical Therapy, Occupational Therapy, Speech language Therapy, and Nutritional Support), By Route of Administration (Oral, Parenteral, and Others), and By End User (Hospitals, Specialty Clinics, and Others), and Regional Forecasts 2022-2028Global Rett Syndrome Market is valued approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2028. The Rett Syndrome can be defined as a rare genetic neurological and developmental disorder that affects the development of the brain. Rett syndrome are caused by a mutation (a change in the DNA) in the MECP2 gene. Rett syndrome is mostly found in females and begins between 8 and 11 years of age and progresses with age. There are different symptoms of Rett Syndrome such as slowed head growth, abnormal hand movements, hyperventilating, screaming, and crying for no obvious reason, difficulty with movement and coordination, and a loss of social interaction and communication. The rising prevalence of neurological disorders and increasing per capita healthcare spending as well as recent approvals from regulatory authorities are accelerating the global market demand. For instance, according to Pan American Health Organization (PAHO) estimates – In 2019, globally Neurological disorders accounted for 533,172 deaths. Around 213,129 (40%) deaths reported in men, whereas around 320,043 (60%) deaths were reported in women. Furthermore, as per The National Center for Biotechnology Information, USA – as of 2020, worldwide 1 in 20 000–40 000 people affected by Rett Syndrome. RTT is most common genetic causes of developmental and intellectual impairment in girls and affects up to 1 in 10 000 girls under the age of 12. Moreover, in April 2022, US based Taysha Gene Therapies launched clinical development of its gene replacement therapy named TSHA-102 for treatment of Rett Syndrome. The company decided to conduct clinical trial after it recently received approval of a clinical trial application (CTA) by Health Canada. The Sainte-Justine Mother and Child University Hospital Center, in Montreal, would be the initial sites for clinical trials. Also, growing number of R&D activities in healthcare sector. And surging healthcare infrastructure in emerging economies are anticipated to act as a catalyzing factor for the market demand during the forecast period. However, high treatment cost and stringent government regulations impede the growth of the market over the forecast period of 2022-2028.

The key regions considered for the global Rett Syndrome Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to growing healthcare expenditure and presence of leading healthcare players in the region. Whereas, Asia Pacific is anticipated to exhibit a significant growth rate over the forecast period 2022-2028. Factors such as growing awareness towards neurological disorders and increasing penetration of leading healthcare companies in the region, would create lucrative growth prospects for the global Rett Syndrome Market across the Asia Pacific region.

Major market players included in this report are:
Merck KGaA (Germany)
Eisai Co., Ltd. (Japan)
AstraZeneca (U.K.)
Sanofi (France)
Novartis AG (Switzerland)
Abbott (U.S.)
F. Hoffmann-La Roche Ltd. (Switzerland)
Teva Pharmaceutical Industries Ltd. (Ireland)
Pfizer Inc. (U.S.)
GlaxoSmithKline plc (U.K.)


The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Type
Classic Rett Syndrome
Atypical Rett Syndrome
By Treatment
Medication
Physical Therapy
Occupational Therapy
Speech language Therapy
Nutritional Support
By Route of Administration
Oral
Parenteral
Others
By End User
Hospitals
Specialty Clinics
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Rett Syndrome Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies Mentioned

Merck KGaA (Germany)
Eisai Co., Ltd. (Japan)
AstraZeneca (U.K.)
Sanofi (France)
Novartis AG (Switzerland)
Abbott (U.S.)
F. Hoffmann-La Roche Ltd. (Switzerland)
Teva Pharmaceutical Industries Ltd. (Ireland)
Pfizer Inc. (U.S.)
GlaxoSmithKline plc (U.K.)

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.